WILMINGTON, Del., Sept. 14, 2020 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase-based therapies
with a first-in-class collagenase-based product marketed as
XIAFLEX® in North
America, today announced that Joseph
Truitt, Chief Executive Officer, will present at the virtual
Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech
Summit on Monday, September 21, 2020
at 4:10 p.m. ET.
A live webcast of the presentations may be accessed by visiting
the Events and Presentations section of the BioSpecifics website at
https://investors.biospecifics.com. An archived replay of the
webcast will be available on the Company's website for
approximately 90 days following the presentation.
About BioSpecifics Technologies Corp.
BioSpecifics
Technologies Corp. is a commercial-stage biopharmaceutical company.
The Company discovered and developed a proprietary form of
injectable collagenase (CCH), which is currently marketed by the
Company's partner, Endo International plc (Endo), as
XIAFLEX® in North
America for the treatment of Dupuytren's contracture and
Peyronie's disease. Endo announced that it received FDA approval of
CCH for the treatment of moderate to severe cellulite in the
buttocks of adult women; Qwo™ is expected to be available
commercially in the U.S. starting in the first half of 2021.
The CCH research and development pipeline includes several
additional potential indications including adhesive capsulitis and
plantar fibromatosis. For more information, please visit
www.biospecifics.com.
Forward-Looking Statements
This press release
includes "forward-looking statements" within the meaning of, and
made pursuant to the safe harbor provisions of, the Private
Securities Litigation Reform Act of 1995. All statements other than
statements of historical fact, including statements regarding the
Company's strategy, future operations, projected prospects, plans
and objectives of management, future strategic opportunities, the
effect of recent management and board leadership changes, the
timing and occurrence of commercial launches, potential
indications, research and development plans, indications in
development, and the assumptions underlying or relating to such
statements, are "forward-looking statements." In some cases, these
statements can be identified by forward-looking words such as
"expect," "plan," "anticipate," "potential," "estimate," "can,"
"will," "continue," "believe," the negative or plural of these
words, and other similar expressions. These forward-looking
statements are predictions based on the Company's current
expectations and the Company's projections about future events and
various assumptions. There can be no assurance that the Company
will realize its expectations or that the Company's beliefs will
prove correct. There are a number of important factors that could
cause the Company's actual results to differ materially from those
indicated by such forward-looking statements, including, but not
limited to: the timing of regulatory filings and action; the
ability of Endo to achieve its objectives for XIAFLEX®
and Qwo™; the market for XIAFLEX® in, and
timing, initiation, and outcome of clinical trials for, additional
indications, which will determine the amount of milestone, royalty,
mark-up on cost of goods sold, license, and sublicense income that
the Company may receive; the potential of XIAFLEX® to be
used in additional indications; Endo modifying its objectives or
allocating resources other than to XIAFLEX® and Qwo™;
the impacts of the novel coronavirus (COVID-19) global pandemic;
and other risk factors identified in the Company's Annual Report on
Form 10-K for the year ended December 31,
2019, and otherwise in its filings and reports filed
with the Securities and Exchange Commission. All forward-looking
statements included in this press release are made as of the date
hereof, are expressly qualified in their entirety by the cautionary
statements included in this press release and, except as may be
required by law, the Company assumes no obligation to update these
forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biospecifics-to-present-at-the-virtual-oppenheimer--co-fall-healthcare-life-sciences-and-medtech-summit-301128193.html
SOURCE BioSpecifics Technologies Corp.